ORIC Pharmaceuticals shares surge 10.57% intraday after selecting rinzimetostat 400 mg combined with darolutamide as the recommended dose for the global Phase 3 Himalayas-1 trial.

ORIC Pharmaceuticals surged 10.57% intraday, as the company announced the selection of rinzimetostat 400 mg combined with darolutamide as the recommended dose for its Himalayas-1 global Phase 3 registration study, based on Phase 1b dose-optimization data, with plans to initiate the trial in the first half of 2026. The company focuses on developing innovative clinical-stage therapies to overcome cancer resistance, with core pipelines including PRC2 inhibitors and EGFR/HER2 exon20 mutation inhibitors.